Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies
Journal of Pharmaceutical Analysis · 2025-09 · 15 (9) · 101250
DOI: 10.1016/j.jpha.2025.101250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2025-09. Verfasst von Man Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Department of Sichuan Province, NSFC.
Abstract (Originalsprache)
Infectious keratitis (IK) is a leading cause of blindness worldwide, primarily resulting from improper contact lens use, trauma, and a compromised immune response. The pathogenic microorganisms responsible for IK include bacteria, fungi, viruses, and Acanthamoeba. This review examines standard therapeutic agents for treating IK, including broad-spectrum empiric antibiotics for bacterial keratitis (BK), antifungals such as voriconazole and natamycin for fungal infections, and antiviral nucleoside analogues for viral keratitis (VK). Additionally, this review discusses therapeutic agents, such as polyhexamethylene biguanide (PHMB), for the treatment of Acanthamoeba keratitis (AK). The review also addresses emerging drugs and the challenges associated with their clinical application, including anti-biofilm agents that combat drug resistance and nuclear factor kappa-B (NF-κB) pathway-targeted therapies to mitigate inflammation. Furthermore, methods of Photodynamic Antimicrobial Therapy (PDAT) are explored. This review underscores the importance of integrating novel and traditional therapies to tackle drug resistance and enhance drug delivery, with the goal of advancing treatment strategies for IK.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
- Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of…
- Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of C…
- Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, 200031, China.
Förderung
- Science and Technology Department of Sichuan Province
- NSFC
Zitieren
APA
Yu, M., Li, L., Liu, Y., Wang, T., Li, H., Shi, C., Guo, X., Wu, W., Gan, C., Li, M., Hong, J., Dong, K., & Gong, B. (2025). Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies. Journal of Pharmaceutical Analysis, 15(9), 101250. https://doi.org/10.1016/j.jpha.2025.101250
Vancouver
Yu M, Li L, Liu Y, Wang T, Li H, Shi C, et al. Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies. Journal of Pharmaceutical Analysis. 2025;15(9):101250. doi:10.1016/j.jpha.2025.101250
BibTeX
@article{Yu2025,
author = {Yu, Man and Li, Ling and Liu, Yijun and Wang, Ting and Li, Huan and Shi, Chen and Guo, Xiaoxin and Wu, Weijia and Gan, Chengzi and Li, Mingze and Hong, Jiaxu and Dong, Kai and Gong, Bo},
title = {Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies},
journal = {Journal of Pharmaceutical Analysis},
year = {2025},
volume = {15},
number = {9},
pages = {101250},
doi = {10.1016/j.jpha.2025.101250}
}
EUVIMED